Clinical Trials on Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line in Japan
Total 83 results
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCLCKorea, Republic of, China, Japan
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZenecaActive, not recruitingAdvanced or Metastatic NSCLCUnited States, Spain, Taiwan, Japan, Italy
-
AstraZenecaDaiichi SankyoRecruitingLocally Advanced or Metastatic Non-Small Cell Lung CancerChina, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
-
AstraZenecaParexelActive, not recruitingLocally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung CancerBelgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
-
AstraZenecaDaiichi SankyoRecruitingAdvanced or Metastatic NSCLCUnited States, Taiwan, Italy, Poland, Spain, Japan, Belgium, Turkey, France, Korea, Republic of
-
TakedaActive, not recruitingAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)United States, Spain, France, Korea, Republic of, Hong Kong, Australia, Taiwan, United Kingdom, Canada, Turkey, Italy, China, Germany, Japan, Austria, Belgium, Greece, Israel, Netherlands, Portugal, Russian Federation, Singapore, Sw... and more
-
ArriVent BioPharma, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768IUnited States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
-
TakedaRecruitingNon-small Cell Lung Cancer (NSCLC)Japan
-
Taiho Oncology, Inc.CompletedAdvanced or Metastatic Non-small Cell Lung CancerUnited States, France, Poland, Spain, Italy, Japan
-
R-PharmCompletedNon-small Cell Lung Cancer (NSCLC)Japan
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLS With Exon 20 Insertion MutationUnited States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
-
Kobe City General HospitalTerminatedAdvanced Non-small Cell Lung CancerJapan
-
Kyowa Kirin Co., Ltd.CompletedAdvanced/Recurrent Non-small-cell Lung CancerJapan
-
AbbVieActive, not recruitingAdvanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
-
Taiho Oncology, Inc.RecruitingAdvanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsUnited States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
-
AstraZenecaParexelActive, not recruitingAdvanced or Metastatic Non-Small Cell Lung CancerUnited States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
-
Janssen Research & Development, LLCActive, not recruitingAdvanced or Metastatic Non-small Cell Lung CancerItaly, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
-
Novartis PharmaceuticalsTerminatedAdvanced Non Small Cell Lung Cancer (NSCLC)France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
-
AstraZenecaCompletedNon-Small Cell Lung Cancer | Advanced Solid Malignancies | Neoplasms, | Metastatic Cancer,Japan
-
ArriVent BioPharma, Inc.Allist Pharmaceuticals, Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 MutationsUnited States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom, Mexico
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
Daiichi SankyoRecruitingNon-Small Cell Lung Cancer (NSCLC)United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Eli Lilly and CompanyCompletedNon-small Cell Lung Cancer MetastaticJapan
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZenecaRecruitingNon-Small Cell Lung Cancer (NSCLC)United States, Korea, Republic of, Taiwan, Japan
-
Eli Lilly and CompanyCompletedColorectal Cancer | Metastatic Melanoma | Advanced Cancer | Metastatic Non-small Cell Lung CancerUnited States, Japan, Australia, France
-
AbbViePfizerActive, not recruitingCancer | Non-small Cell Lung Cancer (NSCLC)United States, Israel, Japan, Korea, Republic of, Spain, Taiwan
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Novartis PharmaceuticalsTerminatedNon-small Cell Lung Cancer (NSCLC)Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
-
Merck Sharp & Dohme LLCActive, not recruiting
-
Hoffmann-La RocheRecruitingNon-small Cell Lung Cancer (NSCLC)Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
-
AstraZenecaActive, not recruitingNon-small Cell Lung Cancer NSCLCUnited Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
-
Astellas Pharma IncTerminatedEGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating MutationsJapan
-
Bristol-Myers SquibbActive, not recruitingNon-Small Cell Lung Cancer (NSCLC)Russian Federation, United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Poland, Puerto Rico, Romania, Spain, Sweden, Swit... and more
-
TakedaCompletedALK-positive Advanced NSCLCJapan
-
PfizerRecruitingNSCLC | Non-Small-Cell Lung CancerSpain, China, Taiwan, France, Singapore, Japan, United States
-
Novartis PharmaceuticalsCompletedAdvanced Non-small Cell Lung CancerSpain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
-
Eisai Inc.CompletedNon-Small Cell Lung Cancer (NSCLC)United States, Taiwan, Hong Kong, Spain, Poland, Singapore, Russian Federation, Italy, Australia, France, Germany, Japan, United Kingdom, Korea, Republic of
-
Hoffmann-La RocheActive, not recruitingNon-small Cell Lung Cancer (NSCLC)United States, Korea, Republic of, Canada, Belgium, China, Denmark, Spain, Thailand, United Kingdom, Taiwan, Brazil, Germany, Mexico, Italy, Switzerland, Hong Kong, Japan, France, Turkey, New Zealand, Poland
-
Hoffmann-La RocheActive, not recruitingNon-small Cell Lung Cancer (NSCLC)United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
-
AmgenRecruitingNon-Small Cell Lung Cancer (NSCLC)United States, Australia, Netherlands, Taiwan, Korea, Republic of, United Kingdom, Spain, Austria, Japan, Switzerland, Sweden, France, Czechia, Italy, Portugal, Hong Kong, Thailand, Singapore, Bulgaria, Turkey, Argentina, Belgium, G... and more
-
Kyowa Kirin, Inc.RecruitingGastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaJapan
-
Astellas Pharma Global Development, Inc.TerminatedNon-small Cell Lung Cancer (NSCLC)United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
-
Genentech, Inc.Hoffmann-La RocheCompletedNon-Squamous Non-Small Cell Lung CancerPoland, Belgium, Spain, United States, Canada, South Africa, Russian Federation, Hong Kong, Taiwan, Japan, France, United Kingdom, Australia, Germany, Hungary, Korea, Republic of, Netherlands, Croatia, Serbia, Israel, Ukraine, Peru, Brazi... and more
-
Taiho Pharmaceutical Co., Ltd.RecruitingGastric Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Alveolar Soft Part Sarcoma | Advanced or Metastatic Solid TumorJapan
-
BayerRecruitingAdvanced Solid Tumors | Non-small Cell Lung CancerUnited States, Korea, Republic of, Israel, Japan, China, Australia
-
AstraZenecaActive, not recruitingAdvanced Non Small Cell Lung CancerCanada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingAdvanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IVSpain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland